Texas 2023 - 88th Regular

Texas House Bill HB826 Latest Draft

Bill / Introduced Version Filed 11/29/2022

Download
.pdf .doc .html
                            88R578 RDS-F
 By: Lambert H.B. No. 826


 A BILL TO BE ENTITLED
 AN ACT
 relating to modification of certain prescription drug benefits and
 coverage offered by certain health benefit plans.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Section 1369.053, Insurance Code, is amended to
 read as follows:
 Sec. 1369.053.  EXCEPTION. This subchapter does not apply
 to:
 (1)  a health benefit plan that provides coverage:
 (A)  only for a specified disease or for another
 single benefit;
 (B)  only for accidental death or dismemberment;
 (C)  for wages or payments in lieu of wages for a
 period during which an employee is absent from work because of
 sickness or injury;
 (D)  as a supplement to a liability insurance
 policy;
 (E)  for credit insurance;
 (F)  only for dental or vision care;
 (G)  only for hospital expenses; or
 (H)  only for indemnity for hospital confinement;
 (2)  a Medicare supplemental policy as defined by
 Section 1882(g)(1), Social Security Act (42 U.S.C. Section 1395ss),
 as amended;
 (3)  a workers' compensation insurance policy;
 (4)  medical payment insurance coverage provided under
 a motor vehicle insurance policy;
 (5)  a long-term care insurance policy, including a
 nursing home fixed indemnity policy, unless the commissioner
 determines that the policy provides benefit coverage so
 comprehensive that the policy is a health benefit plan as described
 by Section 1369.052;
 (6)  the child health plan program under Chapter 62,
 Health and Safety Code, or the health benefits plan for children
 under Chapter 63, Health and Safety Code; [or]
 (7)  a Medicaid managed care program operated under
 Chapter 533, Government Code, or a Medicaid program operated under
 Chapter 32, Human Resources Code; or
 (8)  a self-funded health benefit plan as defined by
 the Employee Retirement Income Security Act of 1974 (29 U.S.C.
 Section 1001 et seq.).
 SECTION 2.  Section 1369.0541, Insurance Code, is amended by
 amending Subsections (a) and (b) and adding Subsections (a-1) and
 (b-1) to read as follows:
 (a)  Except as provided by Section 1369.055(a-1) and
 Subsection (b-1) of this section, a [A] health benefit plan issuer
 may modify drug coverage provided under a health benefit plan if:
 (1)  the modification occurs at the time of coverage
 renewal;
 (2)  the modification is effective uniformly among all
 group health benefit plan sponsors covered by identical or
 substantially identical health benefit plans or all individuals
 covered by identical or substantially identical individual health
 benefit plans, as applicable; and
 (3)  not later than the 60th day before the date the
 modification is effective, the issuer provides written notice of
 the modification to the commissioner, each affected group health
 benefit plan sponsor, each affected enrollee in an affected group
 health benefit plan, and each affected individual health benefit
 plan holder.
 (a-1)  The notice described by Subsection (a)(3) must
 include a statement:
 (1)  indicating that the health benefit plan issuer is
 modifying drug coverage provided under the health benefit plan;
 (2)  explaining the type of modification; and
 (3)  indicating that, on renewal of the health benefit
 plan, the health benefit plan issuer may not modify an enrollee's
 contracted benefit level for any prescription drug that was
 approved or covered under the plan in the immediately preceding
 plan year as provided by Section 1369.055(a-1).
 (b)  Modifications affecting drug coverage that require
 notice under Subsection (a) include:
 (1)  removing a drug from a formulary;
 (2)  adding a requirement that an enrollee receive
 prior authorization for a drug;
 (3)  imposing or altering a quantity limit for a drug;
 (4)  imposing a step-therapy restriction for a drug;
 [and]
 (5)  moving a drug to a higher cost-sharing tier;
 (6)  increasing a coinsurance, copayment, deductible,
 or other out-of-pocket expense that an enrollee must pay for a drug;
 and
 (7)  reducing the maximum drug coverage amount [unless
 a generic drug alternative to the drug is available].
 (b-1)  Modifications affecting drug coverage that are more
 favorable to enrollees may be made at any time and do not require
 notice under Subsection (a), including:
 (1)  the addition of a drug to a formulary;
 (2)  the reduction of a coinsurance, copayment,
 deductible, or other out-of-pocket expense that an enrollee must
 pay for a drug; and
 (3)  the removal of a utilization review requirement.
 SECTION 3.  Section 1369.055, Insurance Code, is amended by
 adding Subsections (a-1), (a-2), and (c) to read as follows:
 (a-1)  On renewal of a health benefit plan, the plan issuer
 may not modify an enrollee's contracted benefit level for any
 prescription drug that was approved or covered under the plan in the
 immediately preceding plan year and prescribed during that year for
 a medical condition or mental illness of the enrollee if:
 (1)  the enrollee was covered by the health benefit
 plan on the date immediately preceding the renewal date;
 (2)  a physician or other prescribing provider
 prescribes the drug for the medical condition or mental illness;
 and
 (3)  the physician or other prescribing provider in
 consultation with the enrollee determines that the drug is the most
 appropriate course of treatment.
 (a-2)  Modifications prohibited under Subsection (a-1)
 include:
 (1)  removing a drug from a formulary;
 (2)  adding a requirement that an enrollee receive
 prior authorization for a drug;
 (3)  imposing or altering a quantity limit for a drug;
 (4)  imposing a step-therapy restriction for a drug;
 (5)  moving a drug to a higher cost-sharing tier;
 (6)  increasing a coinsurance, copayment, deductible,
 or other out-of-pocket expense that an enrollee must pay for a drug;
 and
 (7)  reducing the maximum drug coverage amount.
 (c)  Subsections (a-1) and (a-2) do not:
 (1)  prohibit a health benefit plan issuer from
 requiring, by contract, written policy or procedure, or other
 agreement or course of conduct, a pharmacist to provide a
 substitution for a prescription drug in accordance with Subchapter
 A, Chapter 562, Occupations Code, under which the pharmacist may
 substitute an interchangeable biologic product or therapeutically
 equivalent generic product as determined by the United States Food
 and Drug Administration;
 (2)  prohibit a physician or other prescribing provider
 from prescribing another medication;
 (3)  prohibit the health benefit plan issuer from
 adding a new drug to a formulary;
 (4)  require a health benefit plan to provide coverage
 to an enrollee under circumstances not described by Subsection
 (a-1); or
 (5)  prohibit a health benefit plan issuer from
 removing a drug from its formulary or denying an enrollee coverage
 for the drug if:
 (A)  the United States Food and Drug
 Administration has issued a statement about the drug that calls
 into question the clinical safety of the drug;
 (B)  the drug manufacturer has notified the United
 States Food and Drug Administration of a manufacturing
 discontinuance or potential discontinuance of the drug as required
 by Section 506C, Federal Food, Drug, and Cosmetic Act (21 U.S.C.
 Section 356c); or
 (C)  the drug manufacturer has removed the drug
 from the market.
 SECTION 4.  The changes in law made by this Act apply only to
 a health benefit plan that is delivered, issued for delivery, or
 renewed on or after January 1, 2024. A health benefit plan
 delivered, issued for delivery, or renewed before January 1, 2024,
 is governed by the law as it existed immediately before the
 effective date of this Act, and that law is continued in effect for
 that purpose.
 SECTION 5.  This Act takes effect September 1, 2023.